Defining asthma control
How do patient perceptions of asthma control differ from guideline definitions?
This browser is no longer supported.
To provide you with the best possible experience, we kindly ask you to switch to a supported browser:
Asthma control is influenced by many factors and one often overlooked aspect is particle size.
Relvar’s particle size of 2.3–4.0 μm1 falls well within the optimal range for absorption of 1.0–5.0 μm.2
Relvar is longer acting and more targeted to the appropriate receptors, compared with beclomethasone dipropionate (BDP)/formoterol (Form) (in vitro data)*4–6
Relvar provides significantly greater improvement in lung function vs BDP/Form at 12 months (99% vs 92% FEV1 predicted, p<0.01)7
From educational videos to podcasts, Breathing Space is a GSK initiative designed to share the latest thinking on lung health and provide a space for pulmonologists and other respiratory specialists to gather insights and explore best practice.
*In vitro data: clinical relevance is uncertain.
BDP, beclomethasone dipropionate; FEV1, forced expiratory volume in one second; Form, formoterol; ICS, inhaled corticosteroid; LABA, long-acting β2-agonist.
RELVAR Ellipta was created in collaboration with
Adverse events should be reported directly to the Health Products Regulatory Authority (HPRA) on their website: www.hpra.ie . Adverse events should also be reported to GlaxoSmithKline on 1800 244 255.
Relvar is a registered trademark of the GlaxoSmithKline group of companies
A.G. Last updated: May 2021 PM-IE-FFV-WCNT-210005